Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication.
Eating behavior
Lifestyle
Metabolic syndrome
Psychiatric
Psychotropic medication
Weight gain
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
11
06
2021
accepted:
29
05
2022
medline:
5
6
2023
pubmed:
2
7
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
Many psychiatric patients suffer from overweight/obesity and subsequent metabolic disturbances, where psychotropic medication is one of the main contributors. However, the magnitude of weight gain ranges individually, which leads to questioning the role of other contributors like lifestyle factors. The present study investigated several lifestyle factors among psychiatric inpatients, their relation to biological factors, and their predictive capability for weight gain during treatment. Using a naturalistic observational study design, psychiatric inpatients of all diagnoses were followed for 4 weeks from the start of treatment with weight gain-associated medication. N = 163 participants entered the study. Lifestyle factors were assessed by patient self-report questionnaires. Body weight change over time was calculated relative to baseline body weight. Our study provides three main findings: (1) Obesity and/or metabolic syndrome (metSy) were associated with emotional eating (disinhibition), craving for fast food and sweets, and weight cycling. (2) Patients without metSy and normal BMI experienced increased sweets craving (also for women), a more positive attitude towards drugs, and an improvement of affect (also for men). (3) Sex, presence of metSy and/or drug dosage interacted with disinhibition change, sweets craving change (trend), and fast food craving change to predict weight change over time. Furthermore, drug attitude change interacted with BMI, drug dosage, and presence of metSy to predict weight change. Lifestyle factors, especially eating behaviors, are related to metabolic disturbances and predict weight gain in interaction with clinical parameters.
Identifiants
pubmed: 35778522
doi: 10.1007/s00406-022-01442-4
pii: 10.1007/s00406-022-01442-4
pmc: PMC10238335
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-851Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2012;7(6):e36889
pubmed: 22719834
J Postgrad Med. 2017 Jul-Sep;63(3):182-190
pubmed: 28695871
Int J Eat Disord. 2009 Mar;42(2):104-8
pubmed: 18949767
Diabetes Care. 2005 May;28(5):1063-7
pubmed: 15855568
Obes Rev. 2016 Aug;17(8):691-723
pubmed: 27230851
Acta Psychiatr Scand. 2009 Mar;119(3):171-9
pubmed: 19178394
J Affect Disord. 1994 Mar;30(3):193-207
pubmed: 8006246
Can J Psychiatry. 2012 Jan;57(1):5-12
pubmed: 22296962
J Psychopharmacol. 2013 Apr;27(4):358-65
pubmed: 23343595
Diabetes Care. 2006 Apr;29(4):786-91
pubmed: 16567816
Lancet. 2017 Dec 16;390(10113):2643-2654
pubmed: 28943267
Arch Intern Med. 2007 Apr 23;167(8):802-7
pubmed: 17452543
J Clin Diagn Res. 2017 Jun;11(6):VC05-VC08
pubmed: 28764273
Obes Rev. 2009 Sep;10(5):527-42
pubmed: 19460111
J Psychosom Res. 1985;29(1):71-83
pubmed: 3981480
BMJ Open. 2017 May 29;7(5):e014911
pubmed: 28554922
Transl Psychiatry. 2021 Jun 26;11(1):360
pubmed: 34226496
Front Psychiatry. 2020 Dec 11;11:587486
pubmed: 33362604
PLoS One. 2016 Aug 17;11(8):e0160959
pubmed: 27532610
Eur Arch Psychiatry Clin Neurosci. 2020 Aug;270(5):597-609
pubmed: 31302731
PLoS One. 2020 Dec 3;15(12):e0242569
pubmed: 33270646
J Child Adolesc Psychopharmacol. 2012 Apr;22(2):157-65
pubmed: 22372514
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
World Psychiatry. 2017 Jun;16(2):163-180
pubmed: 28498599
Int Clin Psychopharmacol. 2009 Sep;24(5):257-64
pubmed: 19606055
Psychol Med. 1983 Feb;13(1):177-83
pubmed: 6133297
J Affect Disord. 2014 Jan;152-154:498-504
pubmed: 24095103
Eur Neuropsychopharmacol. 2012 Oct;22(10):747-50
pubmed: 22440974
BMC Public Health. 2017 Mar 21;17(1):275
pubmed: 28327105
Med Arch. 2017 Dec;71(6):412-416
pubmed: 29416202
J Affect Disord. 2016 May;195:88-95
pubmed: 26890288
Circulation. 2016 Nov 1;134(18):e367-e386
pubmed: 27647451
Nat Sci Sleep. 2017 May 19;9:151-161
pubmed: 28579842
Obes Rev. 2015 Feb;16 Suppl 1:7-18
pubmed: 25614199
Asian J Psychiatr. 2018 Feb;32:8-13
pubmed: 29197711
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
J Psychiatr Res. 2009 Mar;43(6):620-6
pubmed: 19110264
Psychopharmacology (Berl). 2019 Nov;236(11):3317-3327
pubmed: 31197435
Sleep Breath. 2016 Sep;20(3):1045-51
pubmed: 27115528
Diabetes Care. 2002 Nov;25(11):1992-8
pubmed: 12401745
Appetite. 2010 Dec;55(3):726-9
pubmed: 20801180
Psychiatry Res. 2012 Dec 30;200(2-3):73-8
pubmed: 22497956
Nutr J. 2014 Dec 16;13(1):117
pubmed: 25516181
J Clin Psychiatry. 2015 Nov;76(11):e1417-23
pubmed: 26646038
Br J Psychiatry. 2013 Jul;203(1):24-34
pubmed: 23661765
JAMA. 2009 Jul 22;302(4):394-400
pubmed: 19622818
J Clin Psychiatry. 2009 Jul;70(7):1041-50
pubmed: 19653979
Diabetol Metab Syndr. 2011 Nov 14;3:30
pubmed: 22082186
Obes Res. 2002 Feb;10(2):107-14
pubmed: 11836456
Nutr Hosp. 2010 Nov-Dec;25(6):984-92
pubmed: 21519770
Int J Obes (Lond). 2008 Nov;32 Suppl 5:S42-8
pubmed: 19011653
PLoS One. 2014 Apr 24;9(4):e94112
pubmed: 24763306
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Gen Hosp Psychiatry. 2009 Sep-Oct;31(5):442-50
pubmed: 19703638
Psychol Med. 1999 May;29(3):697-701
pubmed: 10405091
Schizophr Bull. 2006 Jul;32(3):584-9
pubmed: 16469943
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):490-6
pubmed: 21146575
J Clin Psychiatry. 2015 Jun;76(6):e802-8
pubmed: 26132689
Eat Behav. 2013 Apr;14(2):187-91
pubmed: 23557818
Am J Epidemiol. 1999 Sep 15;150(6):573-9
pubmed: 10489996
Asian J Psychiatr. 2017 Jun;27:139-144
pubmed: 28558888